The RyR2 nucleotide binding site is therefore a potential target for cardiac therapeutic agents not only in ischemia but also in other disease states where arrhythmias arise because of irregularities in SR Ca2+-release through RyR2. The gene discussed is RYR2; the disease is ischemia.